AstraZeneca PLC vs ADMA Biologics, Inc.: SG&A Expense Trends

SG&A Expense Trends: AstraZeneca PLC vs ADMA Biologics, Inc.

In the ever-evolving pharmaceutical industry, understanding the financial strategies of leading companies is crucial. Over the past decade, AstraZeneca PLC and ADMA Biologics, Inc. have shown distinct trends in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, AstraZeneca's SG&A expenses have consistently been over 200 times higher than ADMA's, reflecting its expansive global operations and marketing strategies. Notably, AstraZeneca's expenses peaked in 2022, reaching nearly 19% higher than in 2014, indicating a strategic push in its market presence. Meanwhile, ADMA Biologics has seen a steady increase, with a remarkable 1,125% rise in SG&A expenses over the same period, highlighting its aggressive growth and expansion efforts. These trends underscore the contrasting scales and strategies of these two pharmaceutical players, offering insights into their operational priorities and market dynamics.